Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
GAITHERSBURG, Md., Feb. 11, 2016 -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 25, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of 2015, recent business developments, financial outlook for full year 2016, and revenue guidance for the first quarter of 2016.
This conference call can be accessed live by telephone or through Emergent’s website:
| Live Teleconference Information: Dial in number: (855) 766-6521 International dial in: (262) 912-6157 Passcode: 46021005 | Live Webcast Information: Visit emergentbiosolutions.com and select the “Investors” section |
Pre-registering for the live call will expedite access and minimize hold times. You will be issued a passcode to bypass the operator and connect directly. To pre-register for the call, visit the following website: edge.media-server.com/m/p/9j5eeynk.
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions Inc.
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com.
Follow us on twitter: @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Vice President, Global Public Affairs and Corporate Responsibility 240-631-3394 [email protected]
